Detalhe da pesquisa
1.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
N Engl J Med
; 388(12): 1080-1091, 2023 Mar 23.
Artigo
Inglês
| MEDLINE | ID: mdl-36920778
2.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33891379
3.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33891380
4.
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
N Engl J Med
; 384(6): 512-520, 2021 02 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33567191
5.
Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Allergy
; 2024 Apr 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38563683
6.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38226713
7.
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study.
J Am Acad Dermatol
; 90(3): 504-511, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37866456
8.
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
J Am Acad Dermatol
; 2024 Mar 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38447700
9.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
J Am Acad Dermatol
; 90(4): 775-782, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38122848
10.
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
J Am Acad Dermatol
; 90(3): 494-503, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37951245
11.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
J Am Acad Dermatol
; 90(5): 986-993, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38253129
12.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38451052
13.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Lancet
; 400(10348): 273-282, 2022 07 23.
Artigo
Inglês
| MEDLINE | ID: mdl-35871814
14.
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Br J Dermatol
; 188(3): 330-340, 2023 02 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36751950
15.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Br J Dermatol
; 188(6): 740-748, 2023 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36994947
16.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol
; 89(3): 486-495, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37182701
17.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 89(2): 274-282, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37019386
18.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
J Am Acad Dermatol
; 89(3): 478-485, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37230366
19.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
J Am Acad Dermatol
; 88(1): 29-39, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35820547
20.
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
J Am Acad Dermatol
; 89(6): 1149-1158, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37553030